Evinacumab for the treatment of homozygous familial hypercholesterolemia
Sign Up to like & getrecommendations! Published in 2022 at "Expert Review of Clinical Pharmacology"
DOI: 10.1080/17512433.2022.2047934
Abstract: ABSTRACT Introduction Hypercholesterolemia is mainly caused by abnormal lipoprotein metabolism and can increase the risk of cardiovascular disease. Angiopoietin-like protein 3 (ANGPTL3) can increase low-density lipoprotein cholesterol (LDL-C) and other lipids by inhibiting lipoprotein lipase… read more here.
Keywords: evinacumab treatment; hypercholesterolemia; familial hypercholesterolemia; homozygous familial ... See more keywords